Once daily oral treatment with glucokinase activator TTP399 reduced HbA1c in patients with type 1 diabetes

Findings from the Simplici-T1 trial (NCT03335371) suggest that adding the novel hepatoselective glucokinase activator TTP399 to insulin reduced HbA1c by 0.32% at 12 weeks in type 1 diabetics compared with placebo + insulin.

The Simplici-T1 study was the first to evaluate the activation of glucokinase in patients with type 1 diabetes receiving a daily oral dose of TTP399 as an adjunct to insulin therapy [1]. The primary endpoint of the randomised, double-blind study was a change in HbA1c at week 12.

This study was conducted in 2 parts under the same protocol to evaluate the safety and efficacy of TTP399 in adults with type 1 diabetes. After several weeks of insulin optimisation and placebo run-in, daily dosing with TTP399 was continued for 12 weeks. The 19 patients in part 1 received insulin pump therapy and glucose was continuously monitored. In part 2, 85 patients used an insulin pump or multiple daily insulin injections. Two statistical approaches were used to evaluate the effects of daily 800 mg TTP399 in this second group.

The study achieved its primary endpoint at week 12; HbA1c was reduced by 0.21% in the group receiving TTP399, whereas the placebo group experienced a mean 0.11% increase in HbA1c (P=0.03). A secondary estimand analysis confirmed that patients in the TTP399 arm achieved a placebo-subtracted HbA1c reduction of 0.32% (P=0.001). Treatment-emergent adverse events did not differ between the arms, not even when stratified by system organ class. No diabetic ketoacidosis occurred in either treatment group and no reports of severe hypoglycaemia were reported in the TTP399 arm. Overall, the safety profile was favourable.

1. Valcarce C, et al. The Simplici-T1 trial: activation of glucokinase by TTP399 improves glycaemic control in patients with type 1 diabetes. EASD 2020. Abstract #50.

Posted on 14 December 202016 December 2020